A128.E1200
JACC March 9, 2010
Volume 55, issue 10A

MYOCARDIAL ISCHEMIA AND INFARCTION

A COMPARISON OF CLINICAL OUTCOMES IN THE BYPASS ANGIOPLASTY REVASCULARIZATION INVESTIGATION IN TYPE-2 DIABETES MELLITUS (BARI 2D) BY TYPE OF STENT IMPLANTATION

ACC Poster Contributions
Georgia World Congress Center, Hall B5
Tuesday, March 16, 2010, 9:30 a.m.-10:30 a.m.

Session Title: Stable Ischemic Syndrome--Revascularization in Special Populations
Abstract Category: Stable Ischemic Syndrome
Presentation Number: 1270-321

Authors: *Vankeepuram S. Srinivas, Jiang Lu, John J. Lopez, Jorge Escobedo, GS Das, Zoran S. Nedeljkovic, Vijay Misra, Eric Bates, on behalf of the BARI2D Investigators, Montefiore Medical Center, New York, NY, University of Pittsburgh, Pittsburgh, PA*

Background: Bypass Angioplasty Revascularization Investigation in type-2 Diabetes (BARI2D) reported similar outcomes for medical therapy (Med) and revascularization (Revasc) strategy in diabetic patients (pts) with coronary disease (CAD). Since Drug eluting stents (DES) were available midway through BARI2D, we compared outcomes stratified by DES vs. Bare Metal Stent (BMS) use.

Methods: Overall, 807 pts were randomized to Med, 798 to Revasc (260 DES, 424 BMS,114 excluded for no stent / Revasc after time window). Kaplan-Meier survival analyses was used to compare four-year clinical events and Chi-square test for self-reported angina.

Results: Baseline characteristics of Med and Revasc pts were well matched. Med, BMS and DES pts had similar four-year rates of death, MI, stroke, whereas self-reported angina, equal at baseline, was less in DES and BMS pts over first two years (Table). In subgroup analysis, Death/MI/Stroke rates were similar in DES vs.BMS vs.Med pts with one vessel (19% vs.17% vs.18%,P=0.99), multivessel disease (23% vs.26% vs.24%,P=0.64), myocardial jeopardy <50% (20% vs.21% vs.19%,P=0.92) and >=50% (23% vs.26% vs.27%,P=0.84). At four years, 43% of Med Rx, 32% of BMS and 24% of DES pts required revasc (P<0.0001 for all; P=0.95 for BMS vs.DES).

Conclusions: In BARI2D, a strategy of routine Revasc in diabetic pts with CAD did not improve four year outcomes compared to Med, regardless of stent type. However, DES pts reported less angina at two years, a benefit that was not maintained at four years.

Table: Four-Year Rate of Clinical Events within PCI Stratum of BARI2D

Outcome	Med Rx (N=807)	DES (N=260)	BMS (N=424)	P Value
Death,%	7	8.2	8.8	0.51
MI,%	10.1	8.6	12	0.38
Stroke,%	2.7	2.3	2.6	0.90
Death/MI/Stroke	16.1	17.8	20.5	0.13
Baseline Angina,%	59	60	61	0.92
1-year Angina,%	58	45	49	<0.001
2-year Angina,%	40	28	26	0.005
3-year Angina,%	35	27	33	0.13
4-year Angina,%	29	24	26	0.35